The FDA on July 14, 2022, approved XALKORI® (Crizotinib) for adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory Inflammatory Anaplastic Lymphoma Kinase (ALK)-positive Myofibroblastic Tumors (IMT). XALKORI® (Crizotinib) is a product of Pfizer Inc.
Bottom Ad
Advertisement
Subscribe
